|
Gene: CCT2 |
Gene summary for CCT2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CCT2 | Gene ID | 10576 |
Gene name | chaperonin containing TCP1 subunit 2 | |
Gene Alias | 99D8.1 | |
Cytomap | 12q15 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P78371 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10576 | CCT2 | GSM4909285 | Human | Breast | IDC | 7.99e-10 | 3.74e-01 | 0.21 |
10576 | CCT2 | GSM4909288 | Human | Breast | IDC | 3.04e-02 | -9.84e-02 | 0.0988 |
10576 | CCT2 | GSM4909291 | Human | Breast | IDC | 6.18e-87 | 1.31e+00 | 0.1753 |
10576 | CCT2 | GSM4909296 | Human | Breast | IDC | 3.05e-10 | -2.24e-01 | 0.1524 |
10576 | CCT2 | GSM4909297 | Human | Breast | IDC | 2.55e-13 | -2.03e-01 | 0.1517 |
10576 | CCT2 | GSM4909301 | Human | Breast | IDC | 3.50e-03 | -1.87e-01 | 0.1577 |
10576 | CCT2 | GSM4909311 | Human | Breast | IDC | 2.11e-29 | -3.18e-01 | 0.1534 |
10576 | CCT2 | GSM4909312 | Human | Breast | IDC | 2.57e-11 | -1.88e-01 | 0.1552 |
10576 | CCT2 | GSM4909317 | Human | Breast | IDC | 3.86e-02 | 2.65e-01 | 0.1355 |
10576 | CCT2 | GSM4909319 | Human | Breast | IDC | 5.48e-35 | -3.64e-01 | 0.1563 |
10576 | CCT2 | GSM4909320 | Human | Breast | IDC | 4.80e-15 | 5.44e-01 | 0.1575 |
10576 | CCT2 | GSM4909321 | Human | Breast | IDC | 8.17e-46 | 7.46e-01 | 0.1559 |
10576 | CCT2 | brca1 | Human | Breast | Precancer | 3.87e-09 | 4.08e-01 | -0.0338 |
10576 | CCT2 | brca2 | Human | Breast | Precancer | 2.58e-02 | 2.66e-01 | -0.024 |
10576 | CCT2 | brca3 | Human | Breast | Precancer | 1.98e-03 | 3.06e-01 | -0.0263 |
10576 | CCT2 | NCCBC14 | Human | Breast | DCIS | 8.67e-05 | -6.31e-02 | 0.2021 |
10576 | CCT2 | NCCBC5 | Human | Breast | DCIS | 7.11e-08 | 1.17e-02 | 0.2046 |
10576 | CCT2 | P1 | Human | Breast | IDC | 4.23e-12 | -2.62e-01 | 0.1527 |
10576 | CCT2 | DCIS2 | Human | Breast | DCIS | 4.29e-57 | 2.82e-01 | 0.0085 |
10576 | CCT2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.17e-08 | 3.20e-01 | 0.0155 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00701993 | Endometrium | AEH | establishment of protein localization to chromosome | 10/2100 | 25/18723 | 2.05e-04 | 2.54e-03 | 10 |
GO:005108410 | Endometrium | AEH | 'de novo' posttranslational protein folding | 13/2100 | 39/18723 | 2.08e-04 | 2.58e-03 | 13 |
GO:20005739 | Endometrium | AEH | positive regulation of DNA biosynthetic process | 18/2100 | 66/18723 | 2.52e-04 | 2.99e-03 | 18 |
GO:19043568 | Endometrium | AEH | regulation of telomere maintenance via telomere lengthening | 17/2100 | 61/18723 | 2.80e-04 | 3.21e-03 | 17 |
GO:00519729 | Endometrium | AEH | regulation of telomerase activity | 14/2100 | 47/18723 | 4.51e-04 | 4.76e-03 | 14 |
GO:000072310 | Endometrium | AEH | telomere maintenance | 28/2100 | 131/18723 | 5.62e-04 | 5.62e-03 | 28 |
GO:00701984 | Endometrium | AEH | protein localization to chromosome, telomeric region | 10/2100 | 29/18723 | 8.25e-04 | 7.72e-03 | 10 |
GO:00330446 | Endometrium | AEH | regulation of chromosome organization | 36/2100 | 187/18723 | 8.27e-04 | 7.73e-03 | 36 |
GO:00519739 | Endometrium | AEH | positive regulation of telomerase activity | 11/2100 | 34/18723 | 8.45e-04 | 7.82e-03 | 11 |
GO:00322048 | Endometrium | AEH | regulation of telomere maintenance | 19/2100 | 80/18723 | 1.12e-03 | 9.78e-03 | 19 |
GO:00511319 | Endometrium | AEH | chaperone-mediated protein complex assembly | 8/2100 | 23/18723 | 2.57e-03 | 1.89e-02 | 8 |
GO:00510549 | Endometrium | AEH | positive regulation of DNA metabolic process | 36/2100 | 201/18723 | 3.05e-03 | 2.16e-02 | 36 |
GO:003164717 | Endometrium | EEC | regulation of protein stability | 80/2168 | 298/18723 | 2.48e-13 | 5.96e-11 | 80 |
GO:000645715 | Endometrium | EEC | protein folding | 63/2168 | 212/18723 | 6.82e-13 | 1.40e-10 | 63 |
GO:005082117 | Endometrium | EEC | protein stabilization | 56/2168 | 191/18723 | 2.32e-11 | 3.39e-09 | 56 |
GO:007259415 | Endometrium | EEC | establishment of protein localization to organelle | 94/2168 | 422/18723 | 2.22e-10 | 2.51e-08 | 94 |
GO:190382917 | Endometrium | EEC | positive regulation of cellular protein localization | 67/2168 | 276/18723 | 2.27e-09 | 1.84e-07 | 67 |
GO:190495116 | Endometrium | EEC | positive regulation of establishment of protein localization | 74/2168 | 319/18723 | 2.90e-09 | 2.10e-07 | 74 |
GO:000640315 | Endometrium | EEC | RNA localization | 53/2168 | 201/18723 | 5.20e-09 | 3.47e-07 | 53 |
GO:007020214 | Endometrium | EEC | regulation of establishment of protein localization to chromosome | 9/2168 | 12/18723 | 5.84e-07 | 2.16e-05 | 9 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCT2 | SNV | Missense_Mutation | c.1057N>G | p.Met353Val | p.M353V | P78371 | protein_coding | tolerated(0.07) | benign(0.062) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CCT2 | SNV | Missense_Mutation | c.901N>A | p.Glu301Lys | p.E301K | P78371 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CCT2 | SNV | Missense_Mutation | c.131N>A | p.Gly44Glu | p.G44E | P78371 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CCT2 | SNV | Missense_Mutation | c.196G>C | p.Asp66His | p.D66H | P78371 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | |
CCT2 | SNV | Missense_Mutation | c.1248N>C | p.Leu416Phe | p.L416F | P78371 | protein_coding | tolerated(0.38) | possibly_damaging(0.752) | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CCT2 | SNV | Missense_Mutation | c.898N>T | p.Pro300Ser | p.P300S | P78371 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
CCT2 | SNV | Missense_Mutation | c.1242N>C | p.Glu414Asp | p.E414D | P78371 | protein_coding | deleterious(0.02) | probably_damaging(0.966) | TCGA-MU-A51Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
CCT2 | SNV | Missense_Mutation | novel | c.562N>T | p.Leu188Phe | p.L188F | P78371 | protein_coding | deleterious(0.03) | possibly_damaging(0.837) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CCT2 | SNV | Missense_Mutation | novel | c.1143N>C | p.Gln381His | p.Q381H | P78371 | protein_coding | tolerated(0.52) | probably_damaging(0.991) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
CCT2 | SNV | Missense_Mutation | novel | c.1243N>C | p.Met415Leu | p.M415L | P78371 | protein_coding | tolerated(0.11) | benign(0.091) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |